National Cancer Institute Thai Cancer Anemia Survey

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01030159
Recruitment Status : Completed
First Posted : December 11, 2009
Last Update Posted : April 9, 2014
Information provided by (Responsible Party):
Janssen-Cilag Ltd.,Thailand

Brief Summary:
The purpose of this study is to create a large Thailand database documenting the severity of anemia and its management in the cancer population.

Condition or disease Intervention/treatment
Anemia Cancer Other: Adult Cancer Patients

Detailed Description:
Thai Cancer Anemia Study (TCAS) is a prospective survey that will track anemia management in an adult cancer population. This survey is not intended to interfere with standard medical practices for handling anemia. Information on laboratory values including target and achieved hemaglobin (Hb) levels during chemotherapy cycles, use of blood transfusions, iron supplementation, and epoetin will be collected in addition to information on cancer status and treatment. Data on the level that triggers clinicians to decide on the need for anemia therapy will also be collected. Each patient included in the survey will be followed for six months. Observational Study - No investigational drug administered

Study Type : Observational
Actual Enrollment : 300 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Anemia Survey in Cancer Patients Study
Study Start Date : June 2006
Actual Primary Completion Date : May 2008
Actual Study Completion Date : May 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Anemia
U.S. FDA Resources

Group/Cohort Intervention/treatment
001 Other: Adult Cancer Patients
Tracking anemia management in Adult Cancer Patients

Primary Outcome Measures :
  1. Number of patients that have anemia during cancer therapy [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. Characteristics of patients example treatment duration, type of chemotherapy used, grade of anemia [ Time Frame: 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Anemic patients with cancer receiving chemotherapy

Inclusion Criteria:

  • Patients with cancer

Exclusion Criteria:

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01030159

Bangkok, Thailand
Sponsors and Collaborators
Janssen-Cilag Ltd.,Thailand
Study Director: Janssen-Cilag Ltd Clinical Trial Janssen-Cilag Ltd.

Responsible Party: Janssen-Cilag Ltd.,Thailand Identifier: NCT01030159     History of Changes
Other Study ID Numbers: CR012703
First Posted: December 11, 2009    Key Record Dates
Last Update Posted: April 9, 2014
Last Verified: April 2014

Keywords provided by Janssen-Cilag Ltd.,Thailand:
Cancer Anemia Survey
Thai National Cancer Institute

Additional relevant MeSH terms:
Hematologic Diseases